Overview

Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25 mg With Those of Enbrel®

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
To compare the pharmacokinetic characteristic of LBEC0101 25mg with the active comparator, Enbrel® 25 mg.
Phase:
Phase 1
Details
Lead Sponsor:
LG Life Sciences
Treatments:
Etanercept